In morning activity, Inspire Medical Systems shares declined, slipping 2.3% to $40.41 after Evercore ISI moved the stock from Outperform to In Line and trimmed its price target sharply to $40 from $55. The downgrade emphasized sustained challenges with reimbursement coding and broad uncertainty about the company’s revenue in the near term.
The Evercore analyst highlighted the rejection of Inspire’s standalone CPT code at a May panel meeting as a notable setback. Company management has acknowledged that a realistic timeline for achieving coding uniformity would not arrive until January 2028 at the earliest, according to the analyst’s note cited in the downgrade.
These developments add to a string of bearish analyst actions that have pressured the shares in recent months. Inspire is trading near its 52-week low of $38.91, a steep fall from a 52-week high of $147.03. The stock’s descent has been compounded by disruptions to the company’s WISeR program and by market dynamics tied to GLP-1 drugs, which the Evercore note and other analyst reassessments have flagged as factors shrinking the addressable patient population.
Market conditions provided little offset. The S&P 500 fell 1.4% while the Nasdaq dropped 2.1% in the same session, with a technology-sector selloff linked to concerns about AI-related capital spending depressing risk appetite across equities. The healthcare and medical devices sector was not spared from the broader risk-off mood. With Inspire already trading near multi-year lows, investor confidence remained fragile.
Taken together, the Evercore ISI downgrade - which positions the price target at roughly current trading levels - the uncertain reimbursement pathway, and ongoing operational challenges have converged with a difficult macro environment. Those forces have created a confluence of selling pressure that pushed the stock lower in today’s session. Over the past six months, the shares have lost more than half of their value, a trend cited by analysts reassessing the company’s near-term prospects.
Context and implications
The downgrade centers on two reimbursement-related facts: the denial of a standalone CPT code at a May panel and management’s public assessment that uniform coding is unlikely before January 2028. Both items are presented by the analyst as material constraints on the company’s revenue visibility. Separately, ongoing operational issues associated with the WISeR program and shifts in the patient population due to GLP-1 drugs are identified as additional headwinds.
Finally, the broader market pullback driven by technology sector concerns about AI spending has amplified downward pressure on sentiment toward cyclical and growth-oriented stocks, including those in healthcare and medical devices. For Inspire, the combination of firm-specific and market-wide factors has resulted in the share price moving toward recent lows.